Last reviewed · How we verify
KH176
At a glance
| Generic name | KH176 |
|---|---|
| Also known as | Sonlicromanol |
| Sponsor | Khondrion BV |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases (PHASE3)
- The KHENERGYC Study (PHASE2)
- The KHENEREXT Study (PHASE2)
- The KHENERGYZE Study (PHASE2)
- A Dose-escalating Clinical Trial With KH176 (PHASE1)
- The KHENERGY Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KH176 CI brief — competitive landscape report
- KH176 updates RSS · CI watch RSS
- Khondrion BV portfolio CI